FDA DEVICE FACTS
IntelliVue Patient Monitor 6100 (6100); IntelliVue Patient Monitor 6300 (6300); IntelliVue Patient Monitor 6500 (6500)
Philips Medizin Systeme Böblingen GmbH
FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。
Indications for use
The monitors are indicated for use by health care professionals whenever there is a need for monitoring the physiological parameters of patients. The mon itors are only for use on one patient at a time. The monitors are not therapeutic devices. Caution: The monitors are for prescription use only. The EC G measurement is intended to be used for diagnostic recording of rhythm and detailed morphology of complex cardiac complexes (according to AAMI EC11). ST segment monitoring is i ntended for use with adult patients only and is not clinically validated for use with neonatal and pediatric patients. The SSC Sepsis Protocol, in the Protocol Watch clinical decision support tool, is indicated for use with adult patients only. The derived measurement Pulse Pressure Variation (PPV) is indicated for use with sedated patients receiving controlled mechanical ventilation and mainly free from cardiac arrhythmia. The PPV measurement has been validated only for adult patients. The Masimo rainbow SET measurement is indicated for the noninvasive monitoring of functional oxygen saturation of arterial hemoglobin (SpO2), pulse rate, carboxyhemoglobin saturation (SpCO), methemoglobin saturation (SpMet), total hemoglobin concentration (SpHb), and/or respiratory rate (RRac). The Masimo rainbow SET measurement is indicated for use during both no motion and motion conditions, and for patients who are well or poorly perfused. The Predictive Temperature Module is indicated to provide an accurate prediction of patient temperature using the oral, axillary, or rectal body sites, or to provide an actual temperature reading in the continuous monitor mode to adult and pediatric patients. The NanoPod capnography module is indicated to provide professionally trained health care providers with continuous, non-inv asive measurement and monitoring of carbon dioxide concentration of the expired and inspired breath and respiration rate. It is indi cated for use with neonatal, pediatric, and adult patients in hospitals, hospital-type facilities, intra-hospital transport. The NanoPod capnography module provides the clinician with an integrated pulmonary index (IPI). The IPI is based on end tidal carbon dioxide, respiration rate, oxygen saturation and heart rate. The IPI is a single index of an adult or pediatric patient's v entilatory status displayed on a scale of 1 - 10, where 10 indicates optimal pulmonary status. IPI monitoring displays a single value that represents the patient's pulmonary parameters and alerts clinicians to changes in the patient's pulmonary status. The Integrated Pulmonary In dex (IPI) i s indicated for us e with adult a nd pediatric ( 1 t o 12 y ears) patients only. Warning: The IPI is an adjunct to and not intended to replace vital sign monitoring.
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。